Press Releases Sarepta Therapeutics, Inc.

Equities

SRPT

US8036071004

Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 10:12:18 21/01/2026 pm IST			5-day change	1st Jan Change
21.56 ^USD	+2.50%		-4.78%	+0.88%

13/01	Sarepta reconfirms yearly sales floor for Elevidys of $500.0 mln	RE
13/01	Sector Update: Health Care Stocks Lower in Afternoon Trading	MT

Press Releases

12/01	Sarepta Therapeutics : 2026 JPMorgan Conference	PU
12/01	Sarepta Reports Preliminary* Fourth Quarter and Full-Year 2025 Net Product Revenues	BU
12/01	Johnson Fistel Investigates Sarepta Therapeutics, Inc. (SRPT) Directors for Potential Breaches of Fiduciary Duty	NE
08/01	Sarepta Therapeutics Announces Submission of Clinical Trial Application for SRP-1005, its Investigational Treatment for Huntington's disease	AQ
07/01	Sarepta Therapeutics Announces Submission of Clinical Trial Application for SRP-1005, its Investigational Treatment for Huntington’s Disease	BU
05/01	Sarepta Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference	BU
01/01	Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	BU
11/12	Sarepta Therapeutics Announces Refinancing of Approximately $291 Million of 1.25% Convertible Senior Notes due 2027	BU
25/11	Sarepta Announces Approval to Begin ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with Duchenne	BU
24/11	Sarepta Provides Progress Update for SRP-1003, its Investigational siRNA treatment for Myotonic Dystrophy Type 1	BU
20/11	Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT	PR
17/11	FDA hits Sarepta with liver warning labelling for its DMD drug Elevidys	AQ
15/11	FDA adds strongest warning to Sarepta gene therapy linked to 2 patient deaths	AQ
15/11	Sarepta Announces FDA’s Approval of Updated ELEVIDYS Prescribing Information	BU
04/11	Sarepta Therapeutics : Third Quarter 2025 Earnings Presentation Sarepta Therapeutics	PU
04/11	Sarepta Therapeutics: Q3 Earnings Snapshot	AQ
04/11	Sarepta Therapeutics Announces Third Quarter 2025 Financial Results and Recent Corporate Developments, Including Completion of Its Confirmatory Study, ESSENCE	BU
28/25/28	Sarepta Therapeutics to Announce Third Quarter 2025 Financial Results	BU
11/25/11	Sarepta Therapeutics : O21 Mason et alPooled Cardiac Safety Oral	PU
11/25/11	Sarepta Therapeutics : LBO06 Shieh et alALI EC Late breaker oral presentation	PU
11/25/11	Sarepta Therapeutics : LBP732 Soslow et al Prelim analysis of prophylactic sirolimus (Independent)	PU
11/25/11	Sarepta Therapeutics : P181 Grotski et al Two year old patients efficacy measured by digital endpoints (Independent)	PU
11/25/11	Sarepta Therapeutics : P660 Laine et al Delmox in DMD experience from single center (Independent)	PU
11/25/11	Sarepta Therapeutics : P676 Batley et al One year motor function a single center experience (Independent)	PU
10/25/10	Sarepta Therapeutics : P80 Muntoni et alEMBARK Part 1 2Y vs EC Poster	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

Press Releases Sarepta Therapeutics, Inc.

Equities

SRPT

US8036071004

Pharmaceuticals

Press Releases

Filters